'Plumiaz' off the rose? Acorda CRL means more trials, unknown delay
By Randy Osborne
Friday, May 2, 2014
Acorda Therapeutics Inc.'s second setback in less than a month came in the shape of a complete response letter (CRL) for the new drug application (NDA) related to Plumiaz (diazepam) for epileptic cluster seizures, and the company said the nasal spray version of the benzodiazepine therapy is unlikely to win approval this year.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.